About Emulate
Emulate is a company based in Boston (United States) founded in 2013 by Daniel Levner. Emulate has raised $204.49 million across 9 funding rounds from investors including LabCorp, Cedars Sinai and HHS. Emulate offers products and services including Organ-Chip, Software Platform, Consumables, and BioKits. Emulate operates in a competitive market with competitors including CN Bio, AxoSim, Mimetas, Nortis and NETRI, among others.
- Headquarter Boston, United States
- Founders Daniel Levner
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$204.49 M (USD)
in 9 rounds
-
Latest Funding Round
$82 M (USD), Series E
Sep 07, 2021
-
Investors
LabCorp
& 14 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Emulate
Emulate offers a comprehensive portfolio of products and services, including Organ-Chip, Software Platform, Consumables, and BioKits.
Microfluidic tool for simulating human organ functions in research
Platform for managing and analyzing Organ-Chip experiment data
Materials supporting Organ-Chip operations in laboratory settings
Kits for specific applications like disease modeling
People of Emulate
Unlock access to complete
Unlock access to complete
Funding Insights of Emulate
Emulate has successfully raised a total of $204.49M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $82 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Emulate
Emulate has secured backing from 15 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include LabCorp, Cedars Sinai and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in life sciences & tech sectors
|
Locked | Locked | Locked | |
|
Venture capital investments in technology and defense sectors.
|
Locked | Locked | Locked |
Investor details for Emulate
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Emulate
Investment portfolio details for Emulate
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Emulate
Detailed financials for Emulate
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Emulate Comparisons
Peer comparison for Emulate
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Emulate
Emulate operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CN Bio, AxoSim, Mimetas, Nortis and NETRI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Organ-on-a-chip platforms are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Nerve-on-a-chip technology is advanced by AxoSim for drug development improvement.
|
|
| Locked | Locked | Locked |
Microfluidics-based organ-on-a-chip models for drug evaluation are developed.
|
|
| Locked | Locked | Locked |
Small human tissue segments are generated in microfluidic chips.
|
|
| Locked | Locked | Locked |
Microfluidic devices are developed for industrial applications and brain-on-a-chip models.
|
Detailed competitors of Emulate
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Emulate
Complete news archive for Emulate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emulate
Emulate was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Emulate is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Emulate is a funded company, having raised a total of $204.49M across 9 funding rounds to date.
The company was founded in 2013 in Boston, United States, and operates in the biotechnology sector focused on drug development. In vitro models, including organ-chips for the liver, intestine, kidney, and other organs, are developed to simulate human physiology. These models feature tiny channels lined with living human cells and tissues for predicting responses. Culture modules and analytical software applications are also provided to support research operations.
Emulate's top competitors include CN Bio, Cellbox Labs and Nortis.
Emulate offers Organ-Chip, Software Platform, Consumables, and BioKits.
Emulate has 15 investors. Key investors include LabCorp, Cedars Sinai, HHS, Perceptive Advisors, and ATEL Capital Group.